Peptomyc has announced the closing of a €5 million financing round to support the next stage of development of OMO-103, its therapeutic candidate based on direct MYC inhibition. The financing strengthens the company’s clinical and industrial activity and supports continued progress in oncology.
Financing and investors
The round was led by Alta Life Sciences and Aurora Science, with the participation of new investors including the EIC fund, part of the European Innovation Council, and Laudecum. Existing investor CDTI Innovación also took part again through its Innvierte vehicle.
Use of funds
The funds raised will be used to complete ongoing clinical studies, advance industrial preparation for later development stages, and continue strategic discussions with potential pharmaceutical partners. According to the company, these steps are intended to prepare OMO-103 for its next stage of development.
Project status
Peptomyc describes OMO-103 as the first direct MYC inhibitor with clinical validation, with a favorable safety profile, evidence of target engagement, and early signs of clinical activity. The company currently has three clinical studies underway: a phase 1b trial in metastatic pancreatic cancer, a phase 2 trial in osteosarcoma, and a Window-of-Opportunity study in pancreatic cancer.
Comments